ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Global Regulatory Requirements for Drug Safety & Pharmacovigilance: Product Safety, Effective Risk Assessment, and Alignment with Evolving U.S., EU, and UK Regulatory Expectations (November 25, 2025) - ResearchAndMarkets.com

The "Global Regulatory Requirements for Drug Safety & Pharmacovigilance (November 25, 2025)" training has been added to ResearchAndMarkets.com's offering.

This training course is designed to give pharmaceutical and biologic companies operating in the US and EU an introduction to product safety regulatory requirements.

Product safety makes headlines every day - and the impact on a company's image, consumer confidence, and Wall Street's opinion is profound. Are you confident your current pharmacovigilance operations will meet the latest US, EU and UK expectations for compliance and keep your products on the market? Do you understand the processes needed to perform adequate risk assessment?

Not knowing which systems and processes you must have in place for your own safety reporting could mean you miss an important issue with significant consequences for your product. You must be sure you have the understanding you need to avoid product recall, are able to work to international standards and have implemented regulatory requirements for signalling and risk management.

The course will illustrate the decision-making process and reasoning needed behind when and how to properly report incidents to regulatory authorities.

What You'll Learn

  • An understanding of regulatory requirements for drug safety
  • Overview of US, EU and UK regulatory framework, including details of EU GVP modules and additional requirements for the UK
  • Contents of the PV System Master File (PSMF)
  • Requirements for quality oversight of drug safety
  • Regulations for signal management
  • EU and UK QPPV requirements and responsibilities
  • An engaging and experienced instructor
  • Multiple choice quizzes to test your understanding of the course

Who Should Attend:

Almost everyone involved in drug development and marketing needs to know the basics of worldwide regulations regarding drug safety. Staff who will benefit include:

  • Drug safety and pharmacovigilance
  • Regulatory affairs
  • Clinical development
  • Executives (including C-Level) with any legal responsibility for drug safety

Key Topics Covered:

Global Regulatory Requirements

  • Legalities - US
  • Legalities - EU
  • Penalties for Non-Compliance
  • Matrix of Safety Regulations
  • FDA Regulations
  • FDA Regulation for IND safety reporting
  • IND Annual Report
  • Literature Reporting
  • International Conference on Harmonisation (ICH)
  • ICH Topic Codes and Reports
  • CIOMS
  • Canadian Regulations
  • Key EU Components
  • EU Member States
  • What is Europe? EU, EEA, EFTA
  • EudraVigilance - Pre-Marketing Requirements
  • EudraVigilance - Post-Marketing Requirements
  • EUDRACT
  • EU Clinical Trial Directive
  • EU Clinical Trials Regulation
  • CTIS
  • Qualified Person for Pharmacovigilance (QPPV) requirements
  • Development Safety Update Report
  • European Signaling Regulations

EU Pharmacovigilance Legislation

  • Summary of Requirements
  • Penalties and fees
  • GVP modules
  • Quality systems
  • Audit and inspection
  • PV System Master File (PSMF)

ADR reporting

  • EU and ex-EU Requirements
  • Internet and Social Media
  • Post-Authorisation Studies
  • Biologics

Periodic Safety Update Reports

  • Periodic Benefit-Risk Evaluation Report
  • PSUR Periodicity, ex-EU
  • PSUR Periodicity, EU
  • PSUR (PBRER) New Features
  • PSUR Sections: Detailed Requirements

Signal management

  • MAH Responsibilities
  • Signal Detection
  • Signal Validation
  • EudraVigilance Monitoring
  • EudraVigilance Pilot Program

UK Regulatory Requirements

  • UK QPPV

Quiz Questions

Speakers:

Steve Jolley

DIA

Steve Jolley is a subject matter expert in all areas of global safety compliance and signal detection.

Steve has 37 years' experience in drug safety & pharmacovigilance and has worked with 300 clients in North America, Europe, Japan, India, China, the Middle East, and Africa. He holds degrees in mathematics and computer science from Cambridge University, England. He is an Adjunct Professor at Rutgers University and developed part of their Master's degree in Drug Safety and Pharmacovigilance.

Steve is a featured speaker with FDA, EMA and MHRA at conferences and webinars on auditing, signalling and data mining. He is a member of DIA's training faculty and is an instructor for DIA's Clinical Safety and Pharmacovigilance Certificate Program. In 2010 Steve was elected as chairman of the DIA's Clinical Safety and Pharmacovigilance steering committee for North America.

For more information about this training visit https://www.researchandmarkets.com/r/2yyhed

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+1.37 (0.56%)
AAPL  268.47
-1.30 (-0.48%)
AMD  233.54
-4.16 (-1.75%)
BAC  53.20
-0.09 (-0.17%)
GOOG  279.70
-5.64 (-1.98%)
META  621.71
+2.77 (0.45%)
MSFT  496.82
-0.28 (-0.06%)
NVDA  188.15
+0.07 (0.04%)
ORCL  239.26
-4.54 (-1.86%)
TSLA  429.52
-16.39 (-3.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.